AMBOSS AI Mode vs OpenEvidence (2026)
Clinical questions are the shared entry point for AMBOSS AI Mode and OpenEvidence, but their source collections and commercial models differ. AMBOSS combines conversational answers with its edited reference library; OpenEvidence draws on medical literature and offers free access funded by advertising for eligible clinicians. AMBOSS AI Mode Clinical Care links concise answers to its library, US guidelines and drug information. It can surface conflicting guidance and insufficient information, with clinicians reviewing sources before decisions. Membership costs $29.99 per month on monthly billing, and AI access remains subject to rollout. Current terms prohibit patient information; chart context and structured writeback belong to later development phases. OpenEvidence offers Osler for quick answers, Sackett for deeper investigation and Snow for extended reports. Its content relationships include NEJM, JAMA, Nature, Cochrane and NCCN. Independent studies support the integrity of its citations, which is a separate matter from whether each clinical synthesis is correct. The wider product also includes encounter documentation and patient communication tools, with enterprise terms separate from free individual access. AMBOSS fits clinicians who want conversational access within an established edited reference membership and a workflow without patient data. OpenEvidence fits verified US and Canadian clinicians seeking literature grounded answers across several research depths, alongside optional documentation and communication capabilities.
- An edited reference library should anchor conversational answers.
- Conflicting guideline recommendations need to be visible.
- The workflow can keep patient information out of questions.
- AI access should accompany an existing AMBOSS membership.
- An eligible clinician wants free individual medical search.
- Questions require different depths of literature investigation.
- Journal and specialty guideline content are central to research.
- Documentation or patient communication tools are also relevant.
This comparison is published by AI Health Index, an independent research platform that compares healthcare AI vendors objectively. AMBOSS AI Mode and OpenEvidence are each graded against the same capability taxonomy, from each vendor's own public materials and the regulatory record, under the AI Health Index verification standard. No vendor pays for placement, and no vendor has reviewed this page. How this evidence is graded
Plain facts
| Fact | AMBOSS AI Mode | OpenEvidence |
|---|---|---|
| Primary category | Clinical Reference & Evidence | Clinical Reference & Evidence |
| Founded | Not recorded | 2021 |
| Headquarters | Berlin, Germany | Miami, Florida |
| Website | amboss.com | openevidence.com |
Side by Side
Select any grade to read the note behind it.
Each vendor in one paragraph
Written to be quoted whole. Each paragraph opens the AI Health Index profile of the vendor: what the product is, who buys it and what it does.
AMBOSS AI Mode Clinical Care answers medical questions with short summaries linked to selected sources. It draws on the edited AMBOSS library, US clinical guidelines and a drug database, adapting the presentation to a clinician's specialty. Answers can highlight conflicting recommendations and support follow up exploration of related evidence.
Source: AI Health Index, October 2026
AI medical search and clinical decision support used at the point of care, free to verified United States and Canadian clinicians and funded by pharmaceutical and medical device advertising shown inside the product, with enterprise deployments embedded in the electronic health record at named health systems. The published model family is Osler for direct answers in seconds, Sackett for a more thorough survey.
Source: AI Health Index, October 2026
Questions buyers ask
How do AMBOSS AI Mode and OpenEvidence work with the EHR?
For AMBOSS AI Mode, a research preview demonstrates those later functions in a simulated EHR.
With OpenEvidence, the first party evidence is recent. On 22 September 2026 the company and the University of Texas Medical Branch announced a collaboration putting cited clinical evidence inside the electronic health record, live at UTMB since March 2026, with adoption reported as growing since launch. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified October 15, 2026. No vendor pays for placement.
How are AMBOSS AI Mode and OpenEvidence priced and sold?
AI Mode is currently included in AMBOSS subscriptions, with a possible future premium package disclosed. The site offers a five day trial, but AI access remains subject to rollout and a possible waiting period of several weeks.
For OpenEvidence, the named health system collaborations announced through 2026 carry no commercial terms. It is also not stated whether free individual use by a health system's clinicians creates any institutional obligation before a contract exists. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified October 15, 2026. No vendor pays for placement.
How do AMBOSS AI Mode and OpenEvidence handle patient data?
Provider zero retention does not mean the AMBOSS application stores no input.
In OpenEvidence's case, the scope is narrower than it first looks. The exclusion is drawn around protected health information, not around everything a clinician types. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified October 15, 2026. No vendor pays for placement.
Which settings and specialties do AMBOSS AI Mode and OpenEvidence cover?
For AMBOSS AI Mode, the NOHARM consultation benchmark spans 10 specialties but does not validate every advertised workflow or population. Selected reference content and responsive language support do not by themselves establish equal performance in rare diseases, pediatric contexts or every language.
With OpenEvidence, the product now covers the consultation, the encounter through Visits, and patient contact through the Dialer, with an education platform carrying continuing education and maintenance of certification credit added on 28 July 2026. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified October 15, 2026. No vendor pays for placement.
Related comparisons
Other published head to head assessments involving these vendors or their closest peers.
AMBOSS is based in Berlin, Germany, and OpenEvidence in Miami, Florida. AMBOSS AI access is subject to rollout and possible future premium packaging. OpenEvidence's free tier carries pharmaceutical and medical device advertising; enterprise access has no list price.